Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
.
Physiol Rev. 2021 Sep 6. doi: 10.1152/physrev.00028.2020. Online ahead of print. Physiol Rev. 2021. PMID: 34486393